Leading Japanese maker of patient monitors, ECG machines and defibrillators used in hospitals worldwide.
Leading Japanese maker of patient monitors, ECG machines and defibrillators used in hospitals worldwide.
Sells monitors and diagnostic equipment to hospitals, with disposables such as electrodes and sensors and service contracts keeping revenue coming after the machine is installed. Japanese hospital spending sets the base, and overseas markets, including the US, are a growing share.
In one line: Japan's GE Healthcare for patient monitoring.
Moat: narrow (installed base, brand, regulatory licence). Leading share and installed base in Japanese hospital patient monitoring, expanding overseas on brand trust.
Headquarters: Tokyo, Japan · Founded: 1951 · Employees: 6,116
Size Nihon Kohden (6849.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.55B, the 566th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,519 on 18 Nov 2026.
Performance Over six months the shares gained 2.8%, against -2.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 0.2% over the last twelve months (peer median +8.6%); the operating margin is 7.0% (peer median 9.7%).
Valuation It trades at 18.8× forward earnings against a peer median of 24.5× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.4 points above its cost of capital (5.3% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥230B | ¥235B | ¥225B | ¥222B | ¥207B |
| Revenue growth | — | +4% | +2% | +7% | — |
| Gross profit | ¥122B | ¥118B | ¥114B | ¥109B | ¥103B |
| EBITDA | ¥22.4B | ¥24.6B | ¥24.9B | ¥23.4B | ¥24.9B |
| Net income | ¥12.0B | ¥14.5B | ¥14.1B | ¥17.0B | ¥17.1B |
| Free cash flow | ¥22.6B | ¥15.3B | ¥8.16B | ¥12.0B | -¥9.97B |
| Capital expenditure | ¥7.84B | ¥7.86B | ¥8.71B | ¥4.79B | ¥8.26B |
| Total debt | ¥23.7B | ¥25.2B | ¥26.1B | ¥654M | ¥441M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nihon Kohden 6849.T | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
| Fukuda Denshi 6960.T | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6849.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | -0.1% | 6th lowest of 21 |
| 6-month return | +2.8% | -2.3% | 9th highest of 21 |
| Distance from 52-week high | -19.4% | -26.7% | 8th highest of 21 |
| Revenue growth (TTM) | -0.2% | +8.6% | 4th lowest of 21 |
| Operating margin | 7.0% | 9.7% | 10th lowest of 21 |
| Forward P/E | 18.8× | 24.5× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -3.5% | 11.2% | least demanding of 16 |
| Growth delivered (Del g) | +3.3% | +12.9% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | -6.8 pp | -0.3 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +2.4 pp | -0.1 pp | 10th highest of 21 |
| EV / EBITDA | 9.4× | 14.0× | 4th cheapest of 11 |
| Net debt / EBITDA | -1.6× | 0.8× | 5th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |